Complementary  ||| S:0 E:14 ||| NNP
and  ||| S:14 E:18 ||| CC
Alternative  ||| S:18 E:30 ||| NNP
Medicine  ||| S:30 E:39 ||| NNP
( ||| S:39 E:40 ||| -LRB-
CAM ||| S:40 E:43 ||| NNP
) ||| S:43 E:44 ||| -RRB-
:  ||| S:44 E:46 ||| :
considerations  ||| S:46 E:61 ||| NNS
for  ||| S:61 E:65 ||| IN
the  ||| S:65 E:69 ||| DT
treatment  ||| S:69 E:79 ||| NN
of  ||| S:79 E:82 ||| IN
major  ||| S:82 E:88 ||| JJ
depressive  ||| S:88 E:99 ||| NNS
disorder  ||| S:99 E:108 ||| VBP
The  ||| S:108 E:112 ||| DT
use  ||| S:112 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
complementary  ||| S:119 E:133 ||| JJ
and  ||| S:133 E:137 ||| CC
alternative  ||| S:137 E:149 ||| JJ
medicine  ||| S:149 E:158 ||| NN
( ||| S:158 E:159 ||| -LRB-
CAM ||| S:159 E:162 ||| NNP
)  ||| S:162 E:164 ||| -RRB-
has  ||| S:164 E:168 ||| VBZ
increased  ||| S:168 E:178 ||| VBN
among  ||| S:178 E:184 ||| IN
patients  ||| S:184 E:193 ||| NNS
with  ||| S:193 E:198 ||| IN
psychiatric  ||| S:198 E:210 ||| JJ
disorders ||| S:210 E:219 ||| NNS
,  ||| S:219 E:221 ||| ,
as  ||| S:221 E:224 ||| IN
it  ||| S:224 E:227 ||| PRP
has  ||| S:227 E:231 ||| VBZ
in  ||| S:231 E:234 ||| IN
the  ||| S:234 E:238 ||| DT
general  ||| S:238 E:246 ||| JJ
population ||| S:246 E:256 ||| NN
,  ||| S:256 E:258 ||| ,
over  ||| S:258 E:263 ||| IN
recent  ||| S:263 E:270 ||| JJ
decades ||| S:270 E:277 ||| NNS
.  ||| S:277 E:279 ||| .
Psychiatrists ||| S:279 E:292 ||| NNP
,  ||| S:292 E:294 ||| ,
therefore ||| S:294 E:303 ||| RB
,  ||| S:303 E:305 ||| ,
need  ||| S:305 E:310 ||| VBP
to  ||| S:310 E:313 ||| TO
inquire  ||| S:313 E:321 ||| VB
about  ||| S:321 E:327 ||| RB
and  ||| S:327 E:331 ||| CC
discuss  ||| S:331 E:339 ||| VB
the  ||| S:339 E:343 ||| DT
use  ||| S:343 E:347 ||| NN
of  ||| S:347 E:350 ||| IN
these  ||| S:350 E:356 ||| DT
treatments  ||| S:356 E:367 ||| NNS
with  ||| S:367 E:372 ||| IN
patients  ||| S:372 E:381 ||| NNS
and  ||| S:381 E:385 ||| CC
offer  ||| S:385 E:391 ||| VB
up-to-date  ||| S:391 E:402 ||| JJ
information  ||| S:402 E:414 ||| NN
about  ||| S:414 E:420 ||| IN
risks  ||| S:420 E:426 ||| NNS
and  ||| S:426 E:430 ||| CC
benefits ||| S:430 E:438 ||| NNS
.  ||| S:438 E:440 ||| .
However ||| S:440 E:447 ||| RB
,  ||| S:447 E:449 ||| ,
evidence-based  ||| S:449 E:464 ||| JJ
information  ||| S:464 E:476 ||| NN
is  ||| S:476 E:479 ||| VBZ
limited ||| S:479 E:486 ||| VBN
.  ||| S:486 E:488 ||| .
To  ||| S:488 E:491 ||| TO
address  ||| S:491 E:499 ||| VB
the  ||| S:499 E:503 ||| DT
needs  ||| S:503 E:509 ||| NNS
of  ||| S:509 E:512 ||| IN
practicing  ||| S:512 E:523 ||| VBG
psychiatrists  ||| S:523 E:537 ||| NNS
and  ||| S:537 E:541 ||| CC
the  ||| S:541 E:545 ||| DT
public ||| S:545 E:551 ||| NN
,  ||| S:551 E:553 ||| ,
the  ||| S:553 E:557 ||| DT
American  ||| S:557 E:566 ||| NNP
Psychiatric  ||| S:566 E:578 ||| NNP
Association  ||| S:578 E:590 ||| NNP
has  ||| S:590 E:594 ||| VBZ
set  ||| S:594 E:598 ||| VBN
up  ||| S:598 E:601 ||| RP
a  ||| S:601 E:603 ||| DT
task  ||| S:603 E:608 ||| NN
force  ||| S:608 E:614 ||| NN
on  ||| S:614 E:617 ||| IN
CAM  ||| S:617 E:621 ||| NNP
to  ||| S:621 E:624 ||| TO
review  ||| S:624 E:631 ||| VB
the  ||| S:631 E:635 ||| DT
evidence  ||| S:635 E:644 ||| NN
for  ||| S:644 E:648 ||| IN
the  ||| S:648 E:652 ||| DT
efficacy  ||| S:652 E:661 ||| NN
and  ||| S:661 E:665 ||| CC
safety  ||| S:665 E:672 ||| NN
of  ||| S:672 E:675 ||| IN
CAM  ||| S:675 E:679 ||| NNP
treatments  ||| S:679 E:690 ||| NNS
in  ||| S:690 E:693 ||| IN
major  ||| S:693 E:699 ||| JJ
depressive  ||| S:699 E:710 ||| JJ
disorder  ||| S:710 E:719 ||| NN
( ||| S:719 E:720 ||| -LRB-
MDD ||| S:720 E:723 ||| NNP
) ||| S:723 E:724 ||| -RRB-
.  ||| S:724 E:726 ||| .
Some  ||| S:726 E:731 ||| DT
CAM  ||| S:731 E:735 ||| NNP
treatments  ||| S:735 E:746 ||| NNS
have  ||| S:746 E:751 ||| VBP
known  ||| S:751 E:757 ||| VBN
general  ||| S:757 E:765 ||| JJ
health  ||| S:765 E:772 ||| NN
benefits  ||| S:772 E:781 ||| NNS
but  ||| S:781 E:785 ||| CC
currently  ||| S:785 E:795 ||| RB
equivocal  ||| S:795 E:805 ||| JJ
evidence  ||| S:805 E:814 ||| NN
of  ||| S:814 E:817 ||| IN
benefit  ||| S:817 E:825 ||| NN
in  ||| S:825 E:828 ||| IN
MDD ||| S:828 E:831 ||| NNP
.  ||| S:831 E:833 ||| .
Exercise ||| S:833 E:841 ||| NN
,  ||| S:841 E:843 ||| ,
folate ||| S:843 E:849 ||| NN
,  ||| S:849 E:851 ||| ,
and  ||| S:851 E:855 ||| CC
omega-3  ||| S:855 E:863 ||| CD
fatty  ||| S:863 E:869 ||| CD
acids  ||| S:869 E:875 ||| NNS
can  ||| S:875 E:879 ||| MD
be  ||| S:879 E:882 ||| VB
recommended  ||| S:882 E:894 ||| VBN
to  ||| S:894 E:897 ||| TO
most  ||| S:897 E:902 ||| JJS
patients  ||| S:902 E:911 ||| NNS
with  ||| S:911 E:916 ||| IN
MDD  ||| S:916 E:920 ||| NNP
for  ||| S:920 E:924 ||| IN
their  ||| S:924 E:930 ||| PRP$
general  ||| S:930 E:938 ||| JJ
health  ||| S:938 E:945 ||| NN
benefits ||| S:945 E:953 ||| NNS
,  ||| S:953 E:955 ||| ,
and  ||| S:955 E:959 ||| CC
St  ||| S:959 E:962 ||| NNP
John ||| S:962 E:966 ||| NNP
's  ||| S:966 E:969 ||| POS
wort  ||| S:969 E:974 ||| NN
and  ||| S:974 E:978 ||| CC
S-adenosyl-L-methionine  ||| S:978 E:1002 ||| NNP
( ||| S:1002 E:1003 ||| -LRB-
SAM-e ||| S:1003 E:1008 ||| NNP
)  ||| S:1008 E:1010 ||| -RRB-
may  ||| S:1010 E:1014 ||| MD
be  ||| S:1014 E:1017 ||| VB
appropriate  ||| S:1017 E:1029 ||| JJ
to  ||| S:1029 E:1032 ||| TO
treat  ||| S:1032 E:1038 ||| VB
depression  ||| S:1038 E:1049 ||| NN
in  ||| S:1049 E:1052 ||| IN
some  ||| S:1052 E:1057 ||| DT
patients ||| S:1057 E:1065 ||| NNS
.  ||| S:1065 E:1067 ||| .
In  ||| S:1067 E:1070 ||| IN
all  ||| S:1070 E:1074 ||| DT
instances ||| S:1074 E:1083 ||| NNS
,  ||| S:1083 E:1085 ||| ,
use  ||| S:1085 E:1089 ||| NN
of  ||| S:1089 E:1092 ||| IN
CAM  ||| S:1092 E:1096 ||| NNP
therapies  ||| S:1096 E:1106 ||| NNS
should  ||| S:1106 E:1113 ||| MD
not  ||| S:1113 E:1117 ||| RB
take  ||| S:1117 E:1122 ||| VB
the  ||| S:1122 E:1126 ||| DT
place  ||| S:1126 E:1132 ||| NN
of  ||| S:1132 E:1135 ||| IN
diagnostic  ||| S:1135 E:1146 ||| JJ
assessment  ||| S:1146 E:1157 ||| NN
and  ||| S:1157 E:1161 ||| CC
evaluation  ||| S:1161 E:1172 ||| NN
for  ||| S:1172 E:1176 ||| IN
MDD  ||| S:1176 E:1180 ||| NNP
and  ||| S:1180 E:1184 ||| CC
consideration  ||| S:1184 E:1198 ||| NN
of  ||| S:1198 E:1201 ||| IN
standard  ||| S:1201 E:1210 ||| JJ
treatment  ||| S:1210 E:1220 ||| NN
use ||| S:1220 E:1223 ||| NN
.  ||| S:1223 E:1225 ||| .
Patients  ||| S:1225 E:1234 ||| NNS
should  ||| S:1234 E:1241 ||| MD
receive  ||| S:1241 E:1249 ||| VB
advice  ||| S:1249 E:1256 ||| NN
about  ||| S:1256 E:1262 ||| IN
all  ||| S:1262 E:1266 ||| DT
available  ||| S:1266 E:1276 ||| JJ
treatment  ||| S:1276 E:1286 ||| NN
options ||| S:1286 E:1293 ||| NNS
,  ||| S:1293 E:1295 ||| ,
including  ||| S:1295 E:1305 ||| VBG
risks ||| S:1305 E:1310 ||| NNS
,  ||| S:1310 E:1312 ||| ,
benefits ||| S:1312 E:1320 ||| NNS
,  ||| S:1320 E:1322 ||| ,
and  ||| S:1322 E:1326 ||| CC
possible  ||| S:1326 E:1335 ||| JJ
drug  ||| S:1335 E:1340 ||| NN
interactions ||| S:1340 E:1352 ||| NNS
,  ||| S:1352 E:1354 ||| ,
as  ||| S:1354 E:1357 ||| RB
well  ||| S:1357 E:1362 ||| RB
as  ||| S:1362 E:1365 ||| IN
full  ||| S:1365 E:1370 ||| JJ
evaluations  ||| S:1370 E:1382 ||| NNS
and  ||| S:1382 E:1386 ||| CC
regular  ||| S:1386 E:1394 ||| JJ
monitoring ||| S:1394 E:1404 ||| NN
.  ||| S:1404 E:1406 ||| .
